New findings help explain brain inflammation in Alzheimer's patients

Recent research has triggered a paradigm shift in how we understand Alzheimer’s disease.

For years, scientists viewed brain inflammation as a minor side effect of the condition, but new findings suggest it is a primary driver of the disease, acting as a 'third core pathology.'

The brain's resident immune cells, known as microglia, are central to this process.

This persistent activation leads to the release of toxic proteins that damage neurons and disrupt cognitive function.

Key mechanisms, such as the formation of myddosomes and the chemical modification of the STING protein, keep the immune system stuck in this damaging state.

Scientists have also identified how amyloid proteins interact with Hv1 channels to amplify this inflammatory response.

Importantly, this research highlights that inflammation is a 'double-edged sword.'

Because we need an immune response for brain health, the goal for future therapies is not to eliminate inflammation entirely, but to fine-tune it.

By targeting pathways like TNF-α, researchers hope to develop treatments that can slow cognitive decline, offering new hope for intervention.